Pooled analysis of sustained response rates for extended release quetiapine fumarate as monotherapy or adjunct to antidepressant therapy in patients with major depressive disorder
- 5 September 2013
- journal article
- research article
- Published by Elsevier BV in Journal of Affective Disorders
- Vol. 150 (2), 639-643
- https://doi.org/10.1016/j.jad.2013.01.052
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
This publication has 16 references indexed in Scilit:
- Depressive disorders and suicide: Epidemiology, risk factors, and burdenNeuroscience & Biobehavioral Reviews, 2013
- Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: A placebo-controlled, randomized studyJournal of Affective Disorders, 2011
- A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorderJournal of Affective Disorders, 2010
- Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled studyInternational Journal of Neuropsychopharmacology, 2010
- Extended-Release Quetiapine as Adjunct to an Antidepressant in Patients With Major Depressive DisorderBritish Journal of Psychology, 2009
- Extended Release Quetiapine Fumarate Monotherapy in Major Depressive DisorderPublished by Physicians Postgraduate Press, Inc ,2009
- Rapid Onset of Antidepressant ActionBritish Journal of Psychology, 2008
- Paroxetine with pindolol augmentation: A double-blind, randomized, placebo-controlled study in depressed in-patientsEuropean Neuropsychopharmacology, 2008
- N-Desalkylquetiapine, a Potent Norepinephrine Reuptake Inhibitor and Partial 5-HT1A Agonist, as a Putative Mediator of Quetiapine's Antidepressant ActivityNeuropsychopharmacology, 2007
- Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studiesJournal of Psychiatric Research, 2005